sales-marketing company-profile-60-seconds 
pharmaphorum
FEBRUARY 14, 2022
Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. 101’s immunogenicity and safety profile relative to Shingrix , according to Curevo.
The Pharma Data
AUGUST 3, 2021
Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. The company announced plans to submit donanemab for Alzheimer’s disease and tirzepatide for type 2 diabetes to regulatory authorities by the end of 2021. – Second-quarter 2021 earnings per share (EPS) decreased to $1.53
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 9, 2024
As we delve into the top 15 cardiovascular disease drugs in 2023, guided by comprehensive 2022 sales data, we gain valuable insights into the market trends, drug efficacy and the evolving needs of patients worldwide. Read on to learn more about the top 15 cardiovascular disease drugs in 2023, based on 2022 sales statistics.
The Pharma Data
AUGUST 5, 2020
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1 . vs 0.25) in ASCLEPIOS I and II, respectively ( P < 001 in both studies) (primary endpoints) 1. vs 0.22) and 58% (0.10
The Pharma Data
FEBRUARY 8, 2021
Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%
The Pharma Data
FEBRUARY 4, 2021
Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%
The Pharma Data
APRIL 27, 2021
Q1 2021 sales increase of 2.4% Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. IFRS net sales reported.
Expert insights. Personalized for you.
52 
Let's personalize your content